Borosil Scientific's FY2025-26 annual report shows a company with solid cash generation and a clean audit record, but the numbers carry a consistent pattern of related-party concentration and governance escalation. The most material items are the ₹113.14 crore negative capital reserve from a scheme of arrangement, a loss-making subsidiary that has absorbed repeated capital infusions, and related-party glassware sales to Borosil Limited that are proposed to double to ₹200 crore annually. The auditor has flagged revenue recognition as a key audit matter, and the company's own MD&A contains an internal inconsistency in its growth figures. Promoter holding rose to 68.27% with zero pledge, while the 35th AGM seeks approval for a 20% option-price discount, secondary acquisition of up to 5% of equity through an employee welfare trust, and interest-free company loans to that trust.
Key findings
- Scheme of arrangement created a ₹113.14 crore negative reserve
Major- The Composite Scheme of Arrangement with Borosil Limited and Borosil Technologies Limited, effective 2 December 2023, generated a negative capital reserve of ₹113.14 crore in the standalone financial statements. The scheme also produced a ₹97.81 crore cash receipt in FY2024-25, which dropped to nil in FY2025-26, and the company recognized a ₹51.35 lakh reversal of inventory write-downs in FY2025-26 against a ₹2.26 crore write-down in the prior year. The scheme's accounting treatment is disclosed, but the scale of the negative reserve and the one-time cash inflow warrant scrutiny of how the arrangement was structured and valued. - Loss-making subsidiary Goel Scientific has absorbed repeated capital infusions
Major- Goel Scientific Glass Works Ltd, the group's only subsidiary, reported a loss after tax of ₹4.69 crore in FY2025-26, following losses of ₹6.99 crore in FY2024-25 and ₹8.66 crore in FY2023-24. Borosil Scientific has funded the subsidiary through rights subscriptions and an inter-corporate deposit of ₹11.68 crore that was converted into equity on 27 November 2025, raising its stake from 90.17% to 99.37%. The company has committed to provide further financial support over the next 12 months, and the subsidiary's revenue declined from ₹49.28 crore to ₹44.97 crore in FY2025-26, indicating the losses are structural rather than cyclical. - Related-party glassware sales to Borosil Limited are proposed to double to ₹200 crore
Major- The 35th AGM notice seeks shareholder approval for sale of glassware products to Borosil Limited up to ₹200 crores for FY2027-28, double the ₹100 crore limit approved at the 33rd AGM for FY2024-25. The notice also seeks approval for purchase/sale of raw materials and finished goods up to ₹5 crores per year and functional support/shared services up to ₹30 crores. Consolidated related-party balances with Borosil Limited as at FY2024-25 included a trade receivable of 7.46 crore and current financial assets of 97.81 crore, the latter being the net amount receivable pursuant to the scheme of arrangement. The materiality threshold for related-party transactions is 10% of annual consolidated turnover, and the proposed limits may exceed this threshold. - Promoter holding rose to 68.27% with zero pledge, while CEO remuneration and ESOP terms escalated
Major- Promoter and promoter group shareholding increased from 67.81% to 68.27% between 9 March 2026 and 30 March 2026 via open-market purchases, with no encumbrances declared. The 35th AGM notice proposes increasing the ESOP exercise price discount from 10% to 20% of the closing market price, secondary acquisition of up to 5% of equity through an employee welfare trust, and interest-free financial assistance to that trust up to 5% of paid-up capital and free reserves. CEO remuneration rose from ₹58.50 lakhs in FY2024-25 to ₹60 lakhs in FY2025-26, while commission payable to each non-executive independent director increased from ₹6 lakhs to ₹15 lakhs over the same period. The CEO's re-appointment for another 3 years w.e.f. 2 December 2026 is subject to member approval at the 35th AGM. - Revenue recognition is a standing audit focus, with a single customer above 10% of revenue
Major- Revenue recognition was a key audit matter in FY2024-25 due to the risk of revenue recognized without substantial transfer of control, not in accordance with Ind AS 115, or in the incorrect period, with discounts and rebates processed manually. One customer contributed ₹58.13 crore in FY2025-26, ₹51.88 crore in FY2024-25, and ₹61.76 crore in FY2023-24, exceeding 10% of company revenue in each year. Trade receivables days increased from 56.67 in FY2024 to 58.73 in FY2025 to 59.15 in FY2026, while the FY2024-25 MD&A contains an internal inconsistency stating LabQuest instrumentation sales "grew from ₹42.3 crores to ₹31.9 crores, a 32.3% increase", a direction that conflicts with the figures. - Statutory auditor changed in FY2023-24 after Pathak H. D. & Associates LLP resigned
Minor- Pathak H. D. & Associates LLP resigned as statutory auditors effective 22 May 2023, and Chaturvedi & Shah LLP was appointed in the casual vacancy and confirmed at the 32nd AGM for five consecutive years. The CARO report for FY2023-24 states that the reasons stated by the outgoing auditors were taken into consideration, and no resignations have been reported in FY2024-25 or FY2025-26. The current auditor has served consistently for three years, making this a settled procedural lapse rather than a pattern of auditor turnover. - Operating cash flow has consistently exceeded PAT, but no dividend has been paid in three years
Minor- Consolidated CFO was ₹30.00 crore against PAT of ₹23.48 crore in FY2024, ₹120 crore against PAT of ₹26.72 crore in FY2025, and ₹43.27 crore against PAT of ₹34.58 crore in FY2026, giving CFO/PAT ratios of 1.28x, 4.49x, and 1.25x respectively. No dividend was proposed or paid for any of the three years ended 31 March 2024, 2025, or 2026. The FY2025 cash flow was inflated by the ₹97.81 crore scheme receipt, which dropped to nil in FY2026, and the CFO/PAT ratios remain healthy, indicating the cash flow classification is disclosed rather than abused.
What to watch
- 35th AGM vote on re-appointment of Mr. Vinayak Madhukar Patankar as Whole-time Director & CEO for 3 years w.e.f. 2 December 2026 and his remuneration under Section 197(1).
- Shareholder vote on the proposed ₹200-crore glassware sale limit to Borosil Limited for FY2027-28 at the upcoming AGM.
- Financial support commitment to Goel Scientific Glass Works Ltd over the next 12 months, subject to approvals, as disclosed in the FY2025-26 Annual Report.
Bottom line: Borosil Scientific's cash generation is real and its audit record is clean, but the company's related-party dealings with Borosil Limited are escalating toward ₹200 crore annually, its subsidiary Goel Scientific continues to lose money despite repeated capital infusions, and the 35th AGM seeks approval for ESOP terms that include a deeper discount, secondary acquisition, and interest-free trust funding. The scheme of arrangement created a ₹113.14 crore negative reserve that warrants scrutiny, and revenue recognition was a key audit matter for FY2024-25, with one customer above 10% of revenue in each of the last three years. Watch the AGM votes on CEO re-appointment, the glassware sale limit, and the ESOP trust funding, these will signal whether governance is tightening or loosening.